Navigation Links
ALKS in Medical Technology

Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29

Company to Proceed with Development Program for Oral Compounds to Treat Alcohol Dependence CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc. (Nasdaq: ALKS) today announced positive preliminary results from a clinical trial of ALKS 29 in alcohol dependent patients. Based on these ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...uly 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: alks ) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus((R)) (insulin glargine). Patie...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

..., June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: alks ) today announced long-term, interim results from the DURATION-1 study that showed sustained glucose control with weight loss, as well as improvements...

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

...rary. Clinical trials with the candidate, known as alks 33, began in December 2008. Wentland said the...who performs both basic and applied research. With alks 33 now in clinical development, the team is one ve...d an overview of its product candidates, including alks 33. Preclinical studies of...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

... March 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: alks ) today announced positive results from DURATION-2, the second in a series of studies designed to test the superiority of exenatide once weekly, an in...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

...GE, Mass., Dec. 11 /PRNewswire/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: alks ) today announced that the U.S. Food and Drug Administration (FDA) recently indicated that the ongoing extension of the DURATION-1 study is appropriat...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

...SCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: alks ) today announced results from a 52-week open-label clinical study that showed the durable efficacy of exenatide once weekly, a long-acting release fo...

Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight

...SCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: alks ) announced results from a 30-week study that compared the efficacy of exenatide once weekly, a long-acting release formulation of exenatide, to BYETT...
ALKS in Biological Technology

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

...July 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: alks ) today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration ...

Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes

... May 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: alks ) today announced that a New Drug Application (NDA) for exenatide once weekly has been submitted to the U.S. Food and Drug Administration (FDA). Exena...

Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events

...rch 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: alks ) today announced that a meta-analysis of primary cardiovascular events across controlled clinical studies of three months or greater, from the BYETTA...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...R ) ALEXION PHARMACEUTICALS INC. (NASDAQ: ALXN ) ALKERMES INC. (NASDAQ: alks ) ALLERGAN INC. (NYSE: AGN ) ALLOS THERAPEUTICS INC. (NASDAQ: ALTH ) A... Add ABRAXIS BIOSCIENCE INC NEW (NASDAQ: ABII ) ALKERMES INC (NASDAQ: alks ) AMERISOURCEBERGEN CORP (NYSE: ABC ) APP PHARMACEUTICALS INC (NASDAQ: ...

Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder

...ceuticals, Inc. The formulation is manufactured by Alkermes, Inc. (Nasdaq: alks ). Ortho-McNeil Janssen Scientific Affairs, LLC, funded the study. About ... United States. The formulation is manufactured by Alkermes, Inc. (Nasdaq: alks ). Available in 12.5 mg, 25 mg, 37.5 mg and 50 mg dose units, it is approve...
Other Tags
(Date:2/27/2015)... GA (PRWEB) February 27, 2015 ... Martin Ventures, is collaborating with the Atlanta-based software ... the adoption of Jvion’s advanced predictive capabilities suite ... analytics company that identifies and prevents financial and ... need for predictions that help prevent patient deterioration ...
(Date:2/27/2015)... February 27, 2015 Aligned Modern ... local neighborhood health centers, officially welcomes Dr. Alaina ... based in Aligned Modern Health’s Lincoln Square, Streeterville, ... from the National University of Health Sciences and ... She has completed post-graduate coursework in functional ...
(Date:2/27/2015)... Connecticut Community for Addiction Recovery (CCAR) recently received an ... Centers (ADRC), for its shared Recovery Oriented Employment Services ... 2014 Commissioner’s Recognition Award by the CT Department of ... ROES achieved the highest rate of employment in its ... and other drug addiction. More than half of ...
(Date:2/27/2015)... GA (PRWEB) February 27, 2015 Leading ... and Consumer Protection, PartnerTech Inc. President, Gary ... Association of Georgia (TAG) for the TechAmerica DC ... leaders on legislation regarding technology along with the opportunity ... manufacturer of technology driven products, evidenced by their current ...
(Date:2/27/2015)... Bird B Gone, the leader in ... now offers an effective and humane combo of ... to this bird problem. Rarely have two new products ... problem. , Sparrow Charmer™ Bird Caller Lures them , ... broadcasting Bird B Gone’s proprietary sparrow call. Field tested ...
Breaking Medicine News(10 mins):Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 3Health News:PartnerTech Joins Technology Association of Georgia for TechAmerica DC Fly-In 2Health News:PartnerTech Joins Technology Association of Georgia for TechAmerica DC Fly-In 3Health News:New Sparrow Charmer & Sparrow Sky Trap Combo Delivers One-Two Punch to Sparrow Problem 2Health News:New Sparrow Charmer & Sparrow Sky Trap Combo Delivers One-Two Punch to Sparrow Problem 3
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
Other Contents